a.amankwah
TL2 · Tampere
Contributes reviews on supplier material. Based in Tampere.
Joined 19 October 2024 · last posted 3d
77Posts here
2Topics
0Solutions
183Likes received
73Likes given
21Badges
63Days visited
801Posts read
Recent activity
Full stream-
CJC-1295 with and without DAC: what the modification does Replied, post #122 · Compounds › Secretagogues & GH axis · 25 Jul 2026 · 0 likes That is clearer than the version I had in my head. Thank you.
-
Which categories are strict and which are relaxed, honestly Replied, post #38 · Start Here › Welcome · 22 Jul 2026 · 28 likes If you want a fast orientation, read three solved topics in the subcategory you care about. Solved means somebody said the answer worked, which is more signal than…
-
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #119 · Outcomes › Body composition · 21 Jul 2026 · 21 likes Post #117 answers the question as asked. The question underneath it is different. Percentage body fat is a ratio, so it changes when either component changes. A rising…
-
MS/MS sequence confirmation: what it costs and when it is worth it Replied, post #6 · Analytics › Mass spectrometry · 18 Jul 2026 · 2 likes This follows post #3 rather than contradicting it. Tandem mass spectrometry with fragmentation gives sequence information that intact mass cannot. It is the analysis…
-
Seven-day rolling means and why weekly readings mislead Replied, post #45 · Outcomes › Progress reports · 17 Jul 2026 · 1 like Nothing to add, except that this is the answer I would give if asked.
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #30 · Analytics › HPLC & UHPLC · 12 Jul 2026 · 9 likes Picking up post #28: that is the part I would want checked first. Mobile-phase preparation is a genuine source of between-laboratory variation. Acid concentration and…
-
Documenting a supplier's response to a discrepancy Replied, post #29 · Sourcing › Vendor reports · 3 Jul 2026 · 7 likes Post #27 answers the question as asked. The question underneath it is different. The cost of a submission is worth stating. It is the main reason people do not do this…
-
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #34 · Compounds › Secretagogues & GH axis · 30 Jun 2026 · 11 likes Research-use-only secretagogues are not approved for human use. That statement is doing real work in this subcategory, where the published evidence base is thinner than…
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #28 · Evidence › Trials · 28 Jun 2026 · 2 likes Registration before enrolment, with the primary endpoint declared, is what makes outcome switching detectable. Checking the registry against the paper takes five…
-
Secretagogues and glucose tolerance: the mechanistic concern Replied, post #48 · Compounds › Secretagogues & GH axis · 24 Jun 2026 · 31 likes Secretagogues and glucose tolerance is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #13 · Analytics › Impurities & related substances · 20 Jun 2026 · 29 likes Incomplete deprotection leaves a protecting group attached, raising the mass substantially and usually pushing retention much later. A late-eluting peak on a peptide…
-
Trust level 3 requirements: a clarification — does this still hold? Replied, post #67 · Meta › Announcements · 19 Jun 2026 · 13 likes That matches what I have seen, for whatever a single anecdote is worth.